Kidney Transplant Patients at Increased Risk of Skin Cancer, Even After Graft Stops Working

MedicalResearch.com Interview with
"Kidney Model 9" by GreenFlames09 is licensed under CC BY 2.0. To view a copy of this license, visit: https://creativecommons.org/licenses/by/2.0Donal JSextonMD, PhD
Department of Nephrology and Kidney Transplantation
Beaumont Hospital
Royal College of Surgeons in Ireland
Dublin, Ireland

MedicalResearch.com: What is the background for this study? What are the main findings? 

Response: Patients who receive a kidney transplant as treatment for end stage kidney disease are at risk of malignancy due to immunosuppression. In contrast to

other solid organ transplant types, when kidney transplants fail it is possible for recipients to return to dialysis. Immunosuppression is usually reduced or completely stopped when  the allograft fails due to the risk of infection on dialysis.

We decided to investigate what the trajectory of risk for non-melanoma skin cancer and invasive cancers overall (composite group) looked like for patients who have received multiple consecutive kidney transplants with intervening periods of graft failure. We compared cancer risk during periods of allograft failure and periods of functioning kidney transplants.  

MedicalResearch.com: What should readers take away from your report?

Response: While the risk of skin cancer is higher during periods of functioning transplant than during periods of graft failure, the risk of skin cancer and cancer overall is still higher than the general population during these periods of graft failure.

While it is possible that medical surveillance post transplant contributed to ascertainment bias for non melanoma skin cancer, the trends in overall invasive cancer suggest that physicians looking after patients with failed transplants should be cognizant of the residual elevated risk of malignancy. This may be related to possible lag effects of immunosuppression on cancer development.  

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: Studies aimed at optimizing and individualizing immunosuppressive regimes are needed.

No disclosures.

Citation:

Sexton DJ, O’Kelly P, O’Leary E, et al. Variation in Nonmelanoma Skin Cancer Incidence by Treatment Modality Among Patients Receiving Multiple Kidney Transplants. JAMA Dermatol. Published online February 06, 2019. doi:10.1001/jamadermatol.2018.4660

Feb 11, 2019 @ 6:32 pm

 

 

 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.